Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Bala, Malgorzata M ^a   Celinska Lowenhoff, Magdalena ^a   Padjas, Agnieszka ^a   Szot, Wojciech ^a   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; HUMAN; INTERNATIONAL NORMALIZED RATIO; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SURVIVAL; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

EID: 84964484527     PISSN: 1469493X     EISSN: 13616137     Source Type: Journal    
DOI: 10.1002/14651858.CD012169     Document Type: Review

References (50)

1. Advisory Council for the National Institute of Neurological and Communicative Disorders and Stroke II. Classification and outline of cerebrovascular diseases II. Stroke 1975;6:564-616.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy, antithrombotic therapy and prevention of thrombosis, 9th edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-e88S.
3. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan DSO. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care & Research 2013;65(11):1869-73.
4. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000;31:3067-78.
5. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis and Rheumatism 2002;46:1019-27.
6. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases 2009;68:1428-32.
7. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Current Rheumatology Reports 2010;12:70-6.
8. Chatzikonstantinou A, Wolf ME, Schaefer A, Hennerici MG. Risk prediction of subsequent early stroke in patients with transient ischemic attacks. Cerebrovascular Diseases 2013;36:106-9.
9. Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus October 2014;23(12):1279-82.
10. Chighizola CB, Ubiali T, Meroni PL. Treatment of thrombotic antiphospholipid syndrome: the rationale of current management - an insight into future approaches. Journal of Immunology Research 2015:951424. [DOI: 10.1155/2015/951424]
11. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New England Journal of Medicine 2003;349:1133-8.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
13. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, American Heart Association, American Stroke Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke 2009;40(6):2276.
14. Empson MB, Lassere M, Craig JC, Scott JR. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002859.pub2]
15. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. A randomized double blind placebo controlled trial in asymptomatic antiphospholipid antibody patients. Arthritis & Rheumatism 2007;56:2382-91.
16. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowskie A, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmunity Reviews 2014;13(6):685-96.
17. Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nature Reviews Rheumatology 2015;11(10):586-96.
18. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis 2005;3:848-53.
19. Galli M, Luciani D, Bertolini GL. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101(5):1827-32.
20. George D, Erkan D. Antiphospholipid syndrome. Progress in Cardiovascular Diseases 2009;52:115-25.
21. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109(2):422-30.
22. Giannakopoulos B, Krilis S. The pathogenesis of the antiphospholipid syndrome. New England Journal of Medicine 2013;368(11):1033-44.
23. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. Journal of Autoimmunity 2014;48-49:20-5.
24. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68.
25. Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics. Public Health 2015;129:954-62.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
27. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arteriosclerosis, Thrombosis and Vascular Biology 2001;21:1094-6.
28. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2015;13:2119-26.
29. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology 2012;157:47-58.
30. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome - a systematic review. JAMA 2006;295:1050-7.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719-48.
32. Matyja-Bednarczyk A, Swadzba J, Iwaniec T, Sanak M, Dziedzina S, Cmiel A, et al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thrombosis Research 2014;133(2):173-6.
33. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006;4(2):295-306.
34. Nalli C, Andreoli L, Casu C, Tincani A. Management of recurrent thrombosis in antiphospholipid syndrome. Current Rheumatology Reports 2014;16(3):405.
35. Panichpisal K, Rozner E, Levine SR. The management of stroke in antiphospholipid syndrome. Current Rheumatology Reports 2012;14:99-106.
36. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
37. Pengo V, Ruffatti A, Legnani C, Resele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 2010;8(2):237-42.
38. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118(17):4714-18.
39. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Journal of Autoimmunity 2000;15(2):145-51.
40. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. [Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement]. BMJ 2009;339:b2535. [DOI: 10.1136/bmj.b2535]
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
42. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
43. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20(2):206-18.
44. Saraiva Sda S, Custódio IF, Mazetto Bde M, Collela MP, de Paula EV, Appenzeller S, et al. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thrombosis Research 2015;136(6):1174-8.
45. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis 2005;3:692-4.
46. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
47. Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. British Journal of Clinical Pharmacology 2011;72(4):619-33.
48. Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. British Journal of Clinical Pharmacology 2011;72(4):647-57.
49. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis and Rheumatism 1999;42:1309-11.
50. Woller SC, Stevens SM, Kaplan DA, Branch DW, Aston VT, Wilson EL, et al. Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clinical and Applied Thrombosis/Hemostasis 2016;22(3):239-47. [DOI: 10.1177/1076029615615960]